This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cordis Announces Additional Sizes Of SLEEK® OTW Platform

Stocks in this article: JNJ

Cordis Corporation announced the European CE marking and U.S. Food and Drug Administration (FDA) approval of additional sizes of its SLEEK® OTW platform, a 0.014 inch ultra-low profile percutaneous transluminal angioplasty (PTA) dilatation catheter. The Cordis SLEEK® OTW PTA Dilatation Catheter is a highly deliverable balloon catheter designed to treat patients undergoing peripheral angioplasty procedures below the knee. The SLEEK® OTW catheter was first launched around the world in 2011. Cordis will start commercializing these new sizes immediately in various countries around the world.

Lower limb amputation is a last resort for many patients with end-stage peripheral arterial disease (PAD). It is estimated that as many as 160,000 lower limbs are amputated every year in the U.S. and 60-70 percent of these amputations are performed as the first-line therapy. These lower-limb amputations come with a mortality rate of as much as 70 percent at five years.

The SLEEK® OTW catheter has a unique balance of excellent pushability with a small crossing profile that helps physicians restore blood flow to the lower limbs. As part of the product line extension, Cordis now offers additional lengths of 20mm and 280mm for most of its current diameters. The new 280mm length will enable physicians to treat diffuse disease with fewer inflations. The SLEEK® OTW catheter continues to be the only peripheral balloon offering an ultra low profile 1.25mm diameter option. The addition of these sizes now means that the Cordis SLEEK® OTW platform offers physicians the broadest 0.014 over-the-wire catheter portfolio on the market.

“The SLEEK® OTW catheter has enabled me to treat patients with severe chronic limb ischemia using the Angiosome Concept. Now, more than ever, with the new expanded sizes, we will be able to effectively treat extremely distal lower leg peripheral vascular disease using fewer inflations,” said William Wu, M.D. from the Heart and Vascular Clinic of San Antonio. “I look forward to continue working with Cordis as they bring more products to market that will help provide safe and optimal outcomes for patients.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs